SBRT Versus Conventional Fractionated Radiotherapy for Vertebral Metastases
Primary Purpose
NSCLC
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Metastatic vertebrae treated with SBRT
Sponsored by
About this trial
This is an interventional treatment trial for NSCLC focused on measuring SBRT, NSCLC, Vertebral metastasis
Eligibility Criteria
Inclusion Criteria:
- Pathologically confirmed stage IV non-small cell lung cancer.
- General condition score ≤ 2.
- With vertebral metastases combined with painful symptoms.
- Absence of neurological symptoms due to vertebral metastases, such as dyskinesia, defecation or urination abnormalities.
- No previous radiation treatment of any kind to the vertebral body.
- The metastatic vertebra has not been treated surgically
- Vertebral stability score (SINS) ≤ 12
- Patient life expectancy of more than 6 months.
Exclusion Criteria:
- Small cell cell lung cancer or large cell carcinoma
- General condition score >2, intolerant of radiotherapy.
- Comorbid neurological symptoms such as dyskinesia, abnormal bowel movements or urination
- Metastatic vertebrae that have received radiotherapy or surgical intervention
- Vertebral stability score (SINS) >12
- Patient life expectancy of less than 6 months
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
Test group
Control group
Arm Description
Metastatic vertebrae treated with SBRT
Conventional radiation dose to vertebral metastases
Outcomes
Primary Outcome Measures
Complete pain relief rate
Complete pain relief rate after completion of radiotherapy
Secondary Outcome Measures
Quality of life scores
Quality of life score after radiotherapy
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05577052
Brief Title
SBRT Versus Conventional Fractionated Radiotherapy for Vertebral Metastases
Official Title
SBRT Versus Conventional Fractionated Radiotherapy for Vertebral Metastases From Non-small Cell Lung Cancer, an Open, Randomized Phase II Study
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 30, 2022 (Anticipated)
Primary Completion Date
November 1, 2024 (Anticipated)
Study Completion Date
December 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Wuhan University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Vertebral metastases are events that affect the quality of life of tumor patients, and are often accompanied by severe pain at the site of metastasis and even by the risk of compression fracture. For vertebral metastases who are not yet at risk of vertebral instability fracture, a moderate dose (30Gy/10F) external radiation therapy is the most widely used treatment technique. Previous studies have shown that 60-80% of patients could achieve pain relief with moderate doses of radiation therapy, with median pain control duration of approximately 4 months. Stereotactic Radiation Therapy (SBRT) is currently the most advanced radiation therapy technique. This project proposes to treat vertebral metastases from non-small cell lung cancer using SBRT technology on the True Beam radiotherapy system to compare its efficacy with conventional external irradiation technology in terms of pain relief as well as local control.
Detailed Description
Vertebral metastases are events that affect the quality of life of tumor patients, and are often accompanied by severe pain at the site of metastasis and even by the risk of compression fracture. For vertebral metastases who are not yet at risk of vertebral instability fracture, a moderate dose (30Gy/10F) external radiation therapy is the most widely used treatment technique. Previous studies have shown that 60-80% of patients could achieve pain relief with moderate doses of radiation therapy, with median pain control duration of approximately 4 months.
Stereotactic Radiation Therapy (SBRT) is currently the most advanced radiation therapy technique. It enables focused radiation therapy with small fields through stereotactic techniques. In June 2021, Zhongnan Hospital of Wuhan University introduced the True Beam radiotherapy system, which has a higher treatment rate compared to conventional radiotherapy equipment, while It is the most reliable vehicle to achieve SBRT.
Therefore, this project proposes to treat vertebral metastases from non-small cell lung cancer using SBRT technology on the True Beam radiotherapy system to compare its efficacy with conventional external irradiation technology in terms of pain relief as well as local control.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
NSCLC
Keywords
SBRT, NSCLC, Vertebral metastasis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Test group
Arm Type
Experimental
Arm Description
Metastatic vertebrae treated with SBRT
Arm Title
Control group
Arm Type
Other
Arm Description
Conventional radiation dose to vertebral metastases
Intervention Type
Radiation
Intervention Name(s)
Metastatic vertebrae treated with SBRT
Intervention Description
High-dose SBRT treatment
Primary Outcome Measure Information:
Title
Complete pain relief rate
Description
Complete pain relief rate after completion of radiotherapy
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Quality of life scores
Description
Quality of life score after radiotherapy
Time Frame
3 months and 6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Pathologically confirmed stage IV non-small cell lung cancer.
General condition score ≤ 2.
With vertebral metastases combined with painful symptoms.
Absence of neurological symptoms due to vertebral metastases, such as dyskinesia, defecation or urination abnormalities.
No previous radiation treatment of any kind to the vertebral body.
The metastatic vertebra has not been treated surgically
Vertebral stability score (SINS) ≤ 12
Patient life expectancy of more than 6 months.
Exclusion Criteria:
Small cell cell lung cancer or large cell carcinoma
General condition score >2, intolerant of radiotherapy.
Comorbid neurological symptoms such as dyskinesia, abnormal bowel movements or urination
Metastatic vertebrae that have received radiotherapy or surgical intervention
Vertebral stability score (SINS) >12
Patient life expectancy of less than 6 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jing Yu, Dr
Phone
02767812539
Ext
86
Email
yujingrt@163.com
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Time Frame
2 years of sharing after 3 months
Learn more about this trial
SBRT Versus Conventional Fractionated Radiotherapy for Vertebral Metastases
We'll reach out to this number within 24 hrs